Jeremy Bender Day One Biopharmaceuticals, Inc. (DAWN) insider trading activity

Jeremy Bender is CHIEF EXECUTIVE OFFICER of Day One Biopharmaceuticals, Inc.. Currently has a direct ownership of 654,728 shares of DAWN, which is worth approximately $10.6 Million. The most recent transaction as insider was on May 16, 2024, when has been sold 7,873 shares (Common Stock) at a price of $16.08 per share, resulting in proceeds of $126,597. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 655K

9.29% 3M change

44.49% 12M change

Total Value Held $10.6 Million

Jeremy Bender Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
May 16 2024	SELL Open market or private sale	$126,597 $16.08 p/Share	7,873 Reduced 1.19%	654,728 Common Stock
May 15 2024	BUY Exercise of conversion of derivative security	-	19,999 Added 2.93%	662,601 Common Stock
May 03 2024	SELL Open market or private sale	$163,398 $17.85 p/Share	9,154 Reduced 1.4%	642,602 Common Stock
May 02 2024	SELL Open market or private sale	$107 $17.94 p/Share	6 Reduced 0.0%	651,756 Common Stock
May 01 2024	SELL Open market or private sale	$1,252,511 $17.88 p/Share	70,051 Reduced 9.7%	651,762 Common Stock
Feb 16 2024	SELL Open market or private sale	$116,128 $15.25 p/Share	7,615 Reduced 1.04%	721,813 Common Stock
Feb 15 2024	BUY Exercise of conversion of derivative security	-	19,999 Added 2.67%	729,428 Common Stock

Nov 16 2023	SELL Open market or private sale	$36,320 $11.69 p/Share	3,107 Reduced 0.44%	709,429 Common Stock
Nov 15 2023	BUY Exercise of conversion of derivative security	-	8,312 Added 1.15%	712,536 Common Stock
Aug 17 2023	SELL Open market or private sale	$41,524 $13.86 p/Share	2,996 Reduced 0.42%	704,224 Common Stock
Aug 15 2023	BUY Exercise of conversion of derivative security	-	8,312 Added 1.16%	707,220 Common Stock
Jul 01 2023	SELL Other acquisition or disposition	-	240,288 Reduced 20.37%	939,196 Common Stock
Jul 01 2023	SELL Bona fide gift	-	240,288 Reduced 25.58%	698,908 Common Stock
May 16 2023	SELL Open market or private sale	$40,724 $13.12 p/Share	3,104 Reduced 0.26%	1,179,484 Common Stock
May 15 2023	BUY Exercise of conversion of derivative security	-	8,312 Added 0.7%	1,182,588 Common Stock
Mar 07 2023	SELL Open market or private sale	$250,125 $20.01 p/Share	12,500 Reduced 1.05%	1,174,276 Common Stock
Feb 16 2023	SELL Open market or private sale	$59,140 $19.57 p/Share	3,022 Reduced 0.25%	1,186,776 Common Stock
Feb 15 2023	BUY Exercise of conversion of derivative security	-	8,312 Added 0.69%	1,189,798 Common Stock
Jan 23 2023	SELL Open market or private sale	$275,000 $22.0 p/Share	12,500 Reduced 1.05%	1,181,486 Common Stock
Dec 21 2022	SELL Open market or private sale	$254,000 $20.32 p/Share	12,500 Reduced 1.04%	1,192,424 Common Stock
Nov 21 2022	SELL Open market or private sale	$263,250 $21.06 p/Share	12,500 Reduced 1.03%	1,204,924 Common Stock
Nov 16 2022	SELL Open market or private sale	$32,468 $21.46 p/Share	1,513 Reduced 0.12%	1,217,424 Common Stock
Nov 15 2022	BUY Exercise of conversion of derivative security	-	3,562 Added 0.29%	1,218,937 Common Stock
Nov 01 2022	SELL Open market or private sale	$250,375 $20.03 p/Share	12,500 Reduced 1.02%	1,215,375 Common Stock
Oct 03 2022	SELL Open market or private sale	$250,625 $20.05 p/Share	12,500 Reduced 1.01%	1,227,875 Common Stock

Also insider at

FUSN

Fusion Pharmaceuticals Inc. Healthcare

Director

MREO

Mereo Biopharma Group plc Healthcare

Jeremy Bender

CHIEF EXECUTIVE OFFICER

South San Francisco, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells DAWN shares.

Notify only if

Value

Insider Trading

Get notified when an Day One Biopharmaceuticals, Inc. insider buys or sells DAWN shares.

Notify only if

Operation

Value

Type

News

Receive news related to Day One Biopharmaceuticals, Inc.

Track Activities on DAWN

Account